Lupin gets 2 observations from USFDA for Somerset facility

Lupin Ltd has announced that the U.S. FDA inspected Lupin's Somerset, New Jersey, U.S.A. manufacturing facility from January 2, 2023 to January 13, 2023. The inspection closed with issuance of a Form-483 with two observations.

We are addressing the observations comprehensively and will work with the U.S. FDA to resolve these issues at the earliest. We uphold quality and compliance with utmost importance and are committed to be compliant with CGMP standards across all our facilities.

Shares of Lupin Limited was last trading in BSE at Rs. 755.60 as compared to the previous close of Rs. 754.95. The total number of shares traded during the day was 19197 in over 1541 trades.

The stock hit an intraday high of Rs. 758.85 and intraday low of 747.15. The net turnover during the day was Rs. 14480350.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 USFDA Inspection Form483 2Observations Somerset NewJersey ManufacturingFacility